Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults

BACKGROUND: The anti-retroviral combination of abacavir/lamivudine plus rilpivirine (ABC/3TC/RPV) is not recommended by international guidelines as the first-line regimen. However, it is potent, well-tolerated, and affordable, especially in resource-limited settings. This study evaluates the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Sharlene, Wong, Joshua Guoxian, Ng, Oon Tek, Lee, Cheng Chuan, Leo, Yee Sin, Lye, David Chien Boon, Wong, Chen Seong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243331/
https://www.ncbi.nlm.nih.gov/pubmed/32438914
http://dx.doi.org/10.1186/s12981-020-00272-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243331/
https://www.ncbi.nlm.nih.gov/pubmed/32438914
http://dx.doi.org/10.1186/s12981-020-00272-5

Ejemplares similares